Fluoxetine (Reconcile) for Canine Behavior Disorders

Bottom line

Fluoxetine is the first-line SSRI for canine anxiety, compulsive, and fear-based disorders, and it is the only fluoxetine product FDA-approved for dogs: Reconcile (chewable fluoxetine hydrochloride) is labeled for canine separation anxiety in conjunction with a behavior-modification plan [1]. Dose it at 1–2 mg/kg PO q24h and counsel owners that behavioral benefit typically emerges within 2–4 weeks, with full reassessment by 8 weeks [3] — it is not a situational anxiolytic [1]. It is contraindicated with MAOIs (selegiline/L-deprenyl and the amitraz tick collar) and in dogs with epilepsy or a seizure history, and it carries serotonin-syndrome risk when stacked with other serotonergics [1]. Never use it as monotherapy; efficacy in the pivotal trial required a concurrent behavior plan [1][2].

Drug facts

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). It inhibits presynaptic serotonin reuptake at the synaptic cleft, raising available 5-HT; the clinically meaningful effect emerges over weeks rather than from the acute reuptake block, which is why benefit is delayed.

• MOA: "Fluoxetine exerts its effect by inhibiting the reuptake of serotonin at the pre-synaptic neuron. Fluoxetine does not act as a sedative" [1].
• Metabolism: ~72% oral absorption, then hepatic cytochrome P-450 metabolism to norfluoxetine, an equipotent SSRI that contributes to efficacy. Parent fluoxetine T½ ≈ 6.2 h, but norfluoxetine T½ ≈ 49 h drives the long functional half-life and the extended washout [1].
• Approval status: Reconcile is FDA-approved for canine separation anxiety [1]. Generic fluoxetine is used off-label for aggression, compulsive/stereotypic disorders, other anxiety disorders, and urine marking [4][5].
• Formulations: Reconcile beef-flavored chewable tablets in 8, 16, 32, and 64 mg strengths; generic human fluoxetine (capsules/tablets/oral solution) is used off-label [1].

Indications

On-label: canine separation anxiety, always paired with a behavior-modification plan [1]. The label explicitly notes Reconcile is not recommended for the treatment of aggression and has not been clinically tested for other behavioral disorders [1].

Off-label (generic fluoxetine), supported by peer-reviewed evidence:

• Compulsive/stereotypic disorders — a randomized, controlled trial (63 dogs, 1–2 mg/kg PO q24h) found fluoxetine superior to placebo by week 6 for canine compulsive disorder [5].
• Owner-directed and other aggression — used off-label alongside behavior therapy, despite the Reconcile label's aggression caveat [4]. Set owner expectations carefully and pair with a safety plan.
• Generalized anxiety, noise/fear-based disorders, and urine marking — SSRIs including fluoxetine are used for these presentations in behavioral pharmacology references [4].

Flag off-label use to the owner and document informed consent.

Dosing

1–2 mg/kg PO q24h (0.5–0.9 mg/lb), given with or without food; this is both the Reconcile label dose and the dose used in the separation-anxiety and compulsive-disorder RCTs [1][2][5].

• Titration: many clinicians start at the low end (or ~0.5 mg/kg) for 1–2 weeks to limit early anorexia/sedation, then move to the target dose. If an adverse reaction emerges, a dose reduction resolved or reduced signs in the label field studies, and roughly half of dogs tolerated a return to full dose after 1–2 weeks [1].
• Ceiling: doses above 2 mg/kg/day are not label-supported and carry a higher adverse-effect burden with no established added benefit [1].
• Not PRN: because the effect is neuroadaptive, this is a daily maintenance drug, not a situational anxiolytic. For an acute/event-based need (storms, vet visits), layer a fast-acting agent rather than up-titrating fluoxetine.
• Missed dose: give the next scheduled dose as prescribed; do not double up [1].

Onset & what to tell the owner

Tell owners full behavioral benefit takes about 4–6 weeks and to commit to an adequate trial before judging efficacy. Merck's behavioral-pharmacology reference frames SSRI onset as 7–30 days [4]; the Reconcile label directs reassessment at 8 weeks and reevaluation of case management if there is no improvement by then [1].

Counsel them that:

• Early sedation, reduced appetite, or a transient uptick in anxiety/agitation in the first week or two is common and usually settles [1][4].
• The drug works only alongside the behavior plan — pills without behavior modification "may not provide any lasting benefit" per the label [1].
• They should not stop abruptly on their own or expect a "calming pill" effect the same day.

Adverse effects

The most common signal is appetite suppression and sedation, most pronounced early. In the North American field studies (n=216 treated), reported reactions included calm/lethargy/depression 32.9%, decreased appetite 26.9%, vomiting 17.1%, shaking/shivering/tremor 11.1%, diarrhea 9.7%, and restlessness 7.4% [1].

• Weight loss: ≥5% loss from baseline in 29.6% of treated dogs vs 13.0% of controls — weigh at rechecks [1].
• Neurologic: transient agitation, restlessness, disorientation, or incoordination; seizures were reported even in dogs with no seizure history, so fluoxetine may lower seizure threshold [1].
• Paradoxical: rare increased aggression/agitation — reassess promptly if a dog worsens after starting therapy [1].
• Post-approval reports (decreasing frequency): decreased appetite, depression/lethargy, tremor, vomiting, restlessness/anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, hypersalivation [1].

Drug interactions & contraindications

Contraindicated in dogs with epilepsy or a history of seizures, and should not be combined with seizure-threshold-lowering drugs (e.g., phenothiazines such as acepromazine or chlorpromazine) [1]. Also contraindicated with known hypersensitivity to fluoxetine or other SSRIs [1].

MAOIs — do not combine. Reconcile "should not be given in combination with a monoamine oxidase inhibitor (MAOI) [e.g., selegiline hydrochloride (L-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an MAOI" [1]. Remember amitraz is an MAOI — screen for the amitraz-impregnated tick collar and amitraz dips before starting fluoxetine.

Serotonin syndrome. Stacking fluoxetine with other serotonergic agents — tramadol, trazodone, TCAs (e.g., clomipramine, amitriptyline), other SSRIs, or MAOIs — risks serotonin syndrome (hyperthermia, tremor, agitation, autonomic instability). The label notes TCA co-administration has not been formally studied [1].

Long washout. Because fluoxetine and norfluoxetine have long half-lives, observe a 6-week washout after discontinuing before starting any drug that may adversely interact [1]. Use caution with any agent affecting the CYP450 system (fluoxetine inhibits these enzymes) and in hepatic disease, given hepatic metabolism [1][4].

Monitoring & discontinuation

Reassess at ~4–6 weeks for behavioral response and again by the 8-week mark; if there is no improvement by 8 weeks, reevaluate the diagnosis and case management [1]. At rechecks, track body weight and appetite (the most common tolerability issues) and screen for agitation or any paradoxical worsening [1].

• Baseline physical exam and age-/health-appropriate labs before starting; the label recommends ruling out non-behavioral causes first [1].
• Discontinuation: per the label, because of the long half-life it is not necessary to taper Reconcile, and continued behavior modification is recommended to prevent relapse [1]. In practice, many clinicians still taper after prolonged use, and the drug's own long elimination provides a built-in self-taper.
• Long-term (>8 weeks) effectiveness and safety were not formally evaluated in the pivotal field study, so use professional judgment on continuing therapy and monitor accordingly [1].

Frequently Asked Questions